TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

GALZIN

ZINC ACETATE
Approved 1997-01-28
1
Indication
--
Phase 3 Trials
29
Years on Market

Details

Status
Prescription
First Approved
1997-01-28
Routes
ORAL
Dosage Forms
CAPSULE

Companies

Active Ingredient: ZINC ACETATE

GALZIN Approval History

Loading approval history...

What GALZIN Treats

1 indications

GALZIN is approved for 1 conditions since its original approval in 1997. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Wilson's Disease
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

GALZIN FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Zinc acetate therapy is indicated for maintenance treatment of patients with Wilson’s disease who have been initially treated with a chelating agent (See PRECAUTIONS: Monitoring Patients ).

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.